The 20 Best Non-Hodgkin Lymphoma Doctors Near Me in Maryland, US

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Elite provider by MediFind in the treatment of Non-Hodgkin Lymphoma. She is also highly rated in 22 other conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Elite provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration. Dr. Ambinder is board certified in American Board Of Internal Medicine.

Wyndham Wilson is an Oncologist practicing medicine in Bethesda, Maryland. Dr. Wilson is rated as an Elite provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Burkitt Lymphoma.

Mark Roschewski is a Hematologist practicing medicine in Bethesda, Maryland. Dr. Roschewski is rated as an Elite provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Smoldering Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), and Vitrectomy.

Aaron Rapoport is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Rapoport is rated as an Elite provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Transplant. Dr. Swinnen is board certified in American Board Of Internal Medicine.

Dr. Sterling is an oncologist who cares for patients with hematologic malignancies at the Johns Hopkins University School of Medicine. He is an active clinician with expertise in lymphoma and bone marrow transplantation and serves as the Director of the Johns Hopkins Lymphoma and Myeloma Multidisciplinary Conference. Dr. Sterling earned his undergraduate degree in biomedical sciences from Auburn University and his medical degree from Johns Hopkins University. He completed his training in internal medicine and medical oncology at Johns Hopkins before being recruited to the faculty. As a clinical investigator, Dr. Sterling's research focuses on the development of new technologies, therapies, and treatment strategies for lymphoma and other conditions treated with bone marrow transplantation. Dr. Sterling is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, T-Cell Lymphoma, and Peripheral T-Cell Lymphoma. Dr. Sterling is board certified in American Board Of Internal Medicine.

Blanche Mavromatis, MD, specializes in hematology oncology and is board certified in internal medicine by the American Board of Internal Medicine. Dr. Mavromatis completed her fellowship at Georgetown University Hospital, residency at Georgetown University Medical Center and medical degree from Thomas Jefferson University Medical College. Dr. Mavromatis is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. She is also highly rated in 67 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Chronic Lymphocytic Leukemia (CLL), and Richter Syndrome. Dr. Mavromatis is board certified in American Board Of Internal Medicine. Dr. Mavromatis is currently accepting new patients.

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty. Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program. In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia. Dr. Jones is rated as an Advanced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Non-Hodgkin Lymphoma, and Myelodysplastic Syndrome (MDS). Dr. Jones is board certified in American Board Of Internal Medicine.

Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is rated as an Advanced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Glioma, Glioblastoma, Astrocytoma, and Brain Tumor. Dr. Holdhoff is board certified in American Board Of Internal Medicine.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Advanced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration. Dr. Fuchs is board certified in American Board Of Internal Medicine.

As a physician scientist in the hematological malignancies and stem cell transplantation division with Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins, my focus is on the various aspects of cellular therapy in the treatment of hematological malignancies. My primary research focus is to develop strategies to prevent relapse of hematological malignancies following allogeneic stem cell transplantation. Additionally, I serve as the director of the adult CAR T program for hematological malignancies as we grow our CAR T program to help patients with advanced hematological malignancies. My academic interest in this space lies in studying the aspects of toxicity of CAR T cell therapy with an aim to improve long term outcomes in these patients. Among hematological malignancies, myeloproliferative disorders are my area of interest and I work to study newer drugs in early phase of development and also its treatment using allogeneic stem cell transplantation. Patient appointments: 410-955-8893. Dr. Jain is rated as an Advanced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Myelofibrosis, Myeloproliferative Neoplasms (MPN), Splenomegaly, Bone Marrow Transplant, and Splenectomy. Dr. Jain is board certified in American Board Of Internal Medicine.

Learn more at marylandoncology.com. Dr. Sastry is rated as an Advanced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. She is also highly rated in 52 other conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Iron Deficiency Anemia, and Childhood Iron Deficiency Anemia. Dr. Sastry is board certified in American Board Of Internal Medicine.

Seung Lee is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 29 other conditions, according to our data. His clinical expertise encompasses Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Bone Marrow Aspiration, and Splenectomy.

Qamar Zaman is an Oncologist practicing medicine in Cumberland, Maryland. Dr. Zaman is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 71 other conditions, according to our data. His clinical expertise encompasses Anal Cancer, Thrombocytopenia, Non-Hodgkin Lymphoma, Gastric Lymphoma, and Bone Marrow Aspiration.

Christopher Melani is a primary care provider, practicing in Hematologist in Baltimore, Maryland. Dr. Melani is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Lymphomatoid Granulomatosis, Primary Mediastinal B-Cell Lymphoma (PMBCL), B-Cell Lymphoma, and Non-Hodgkin Lymphoma.

Ashkan Bahrani is a Hematologist and an Oncologist practicing medicine in Bel Air, Maryland. Dr. Bahrani is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 44 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Lung Cancer, Colorectal Cancer, and Familial Colorectal Cancer. Dr. Bahrani is currently accepting new patients.

Robert Donegan is a Hematologist practicing medicine in Towson, Maryland. Dr. Donegan is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Non-Hodgkin Lymphoma, and Angiosarcoma.

Panayotis Ledakis is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Ledakis is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 79 other conditions, according to our data. His clinical expertise encompasses Appendix Cancer, Desmoplastic Small Round Cell Tumor, Anemia, Colorectal Cancer, and Ureteroscopy.

Gurdeep Chhabra is a Hematologist practicing medicine in Riverdale, Maryland. Dr. Chhabra is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 37 other conditions, according to our data. His clinical expertise encompasses Inflammatory Breast Cancer, Paget Disease of the Breast, Colorectal Cancer, and Small Cell Lung Cancer (SCLC).